ULCER AND GENETIC MARKERS OF PHARMACOKINETICS: INTERRELATION AND FEATURES
Article Sidebar
Main Article Content
Abstract
The article reveals the results of a study of the relationship between the genotypes of the CYP2C19 gene in patients with gastric and duodenal ulcers and the manifestation of concomitant diseases. Recommendations are given for the personification of peptic ulcer pharmacotherapy, taking into account genetic markers of pharmacokinetics.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Abdashimov Zafar. To study the prevalence of alleles and genotypes of two polymorphic markers of the cyp 2c9 and CYP2C19 gene. Journal of Biomedicin eand Practice. 2022, vol. 7, issue 1,pp.29-34 DOI: http://dx.doi.org/10.5281/zenodo.6404443
Baldwin R.M., Ohlsson S., Pedersen R.S. et al. (2018) Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br. J. Clin. Pharmacol., 65(5): 767–774.
Begaud В, Dangoumau J. Pharmacoepidemiology: definitions, problems, methodology. Therapie2020;55(suppl.1): 113-117
Bjerrum L, Sogaard J, Hallas J, Kragstrup J. Poiypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol 2018;54(suppl. 3):192-202.
B.I. Kantemirova, E.A. Orlova, O.S. Polunina, E.N. Chernysheva, M.A. Abdullaev, D.A. Sychev. Pharmacogenetic bases of individual sensitivity and personalized administration of antiplatelet therapy in various ethnic groups. Pharmacy and pharmacology. 2020;8(6):392-404. DOI: 10.19163/2307-9266-2020-8-6-392-404
Denisenko N. P. et al. The frequency of polymorphisms of the CYP2C19 gene associated with an altered pharmacological response to proton pump inhibitors in Russian patients with peptic ulcer disease //Molecular medicine. – 2015. – No. 5. – pp. 58-61.
Elokhina E. V., Skalsky S. V., Gudinova Zh. V. Genotyping by CYP2C19 of patients with acid-dependent lesions of the stomach and duodenum as the basis of personalized pharmacotherapy //Medical technologies. Evaluation and selection. – 2013. – №. 1 (11). – Pp. 57-62.
Effect of polymorphism of genes of platelet receptors P2RY12, ITGB3 and cytochrome CYP2C19 metabolizer enzyme on platelet activity and effectiveness of clopidogrel in patients with stable angina pectoris living in the Grodno region / T. P. Pronko [et al.] // Weight. National Academy of Sciences. navuk Belarussi. Ser. med. navuk. – 2021. – Vol. 18, No. 2. – pp. 147-159. https://doi.org/10.29235/1814-6023-2021-18-2-147-159
Karimovna K. F. SIGNS OF GENOTYPICAL FEATURES IN GASTRIC ULCER AND FEATURES OF TREATMENT //E-Conference Globe. – 2021. – С. 30-32.
Kurupanova AS, Lareva NV. Polymorphism of the genes MDR1, CYP2C19*2, *17 in men and women with acute coronary syndrome with ST segment elevation.Siberian Medical Review. 2019;(4):74-80. DOI: 10.20333/2500136-2019-4-74-80
Klichova F. K. Polymorphism of genes is factor efficiency anti ulcer pharmacotherapy //ACADEMICIA: An International Multidisciplinary Research Journal. – 2021. – Т. 11. – №. 3. – С. 222-228.
Klichova F. K., Mavlyanov I. R., Musaeva D. M. INFLUENCE OF GENES ON PHARMACOTHERAPY OF ULCER DISEASE //A new day in medicine. – 2020. – No. 2. – pp. 147-150
N.K.Kulmyrzayeva, N.A.Seitmaganbetova, G.A.Smagulova, G.V.Veklenko, G.S.Kurmasheva, A.A.Zhaubatyrova, N.A. Zhumakhanova, G.B. Abdrakhmanova Prevalence of CYP2C19 gene polymorphism in residents of Aktobe region // Bulletin of KazNMU. 2015. №4. URL: https://cyberleninka.ru/article/n/rasprostranennost-polimorfizma-gena-cyp2c19-u-zhiteley-aktyubinskoy-oblasti
Musaeva D.M. Personification of pharmacotherapy – the requirement of time // ICLX. 2022. No. 1. URL: https://cyberleninka.ru/article/n/personifikatsiya-farmakoterapii-trebovanie-vremeni
Makushina A. A. et al. CYP3A5*3 polymorphism and features of proton pump inhibitor metabolism in patients with peptic ulcer disease //Pharmacogenetics and pharmacogenomics. – 2017. – No. 2. – pp. 17-17.
Maximov M. L. et al. General issues of clinical pharmacology and pharmacotherapy. – 2020.
Ochilov A. K., Musaeva D. M. Features of the CYP2C19 gene for individualization of pharmacotherapy //A new day in medicine. – 2020. – No. 1. – pp. 65-68.
Ochilov A. K., Musaeva D. M. Features of the CYP2C19 gene for individualization of pharmacotherapy //A new day in medicine. – 2020. – No. 1. – pp. 65-68.